SCHEDULE: Vanguard Group Amends AngioDynamics Stake Reporting

The Vanguard Group has filed an amendment to its Schedule 13G for AngioDynamics Inc., reporting 0% beneficial ownership due to an internal corporate realignment.

Summary

• The Vanguard Group, Inc. filed an Amendment No. 7 to its Schedule 13G regarding its beneficial ownership of Common Stock in AngioDynamics Inc.
• As a result of an internal realignment on January 12, 2026, The Vanguard Group, Inc. now reports 0 shares beneficially owned, representing 0% of the class.
• Previously, certain subsidiaries or business divisions of The Vanguard Group, Inc. were deemed to have beneficial ownership with the parent entity.
• Following the realignment, these subsidiaries and business divisions will report their beneficial ownership separately, in reliance on SEC Release No. 34-39538.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over the securities now reported by these disaggregated entities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It primarily reflects an administrative change in how The Vanguard Group reports its beneficial ownership due to an internal realignment, rather than a change in investment sentiment towards AngioDynamics Inc.

Positives

• The change is administrative, reflecting an internal restructuring at Vanguard rather than a divestment decision related to AngioDynamics' performance.

Negatives

• The Vanguard Group, Inc. now reports 0% beneficial ownership, which might be misinterpreted as a complete divestment if the context of the internal realignment is not fully understood.

Risks

• No specific risks related to AngioDynamics Inc. were mentioned in this administrative filing.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding AngioDynamics Inc. or The Vanguard Group's future investment strategies beyond the reporting realignment.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that large investment managers like The Vanguard Group periodically undergo internal restructurings to optimize operational efficiency or comply with evolving regulatory interpretations. This realignment affects how beneficial ownership is reported across their various funds and divisions, rather than signaling a change in investment thesis for AngioDynamics Inc. specifically.

Stakeholder Impact

• Shareholders of AngioDynamics Inc. may initially perceive a decrease in institutional ownership, but understanding the administrative nature of Vanguard's realignment clarifies that it is not a divestment based on company performance.
• The primary impact is on The Vanguard Group's internal reporting structure and its various subsidiaries/business divisions, which will now report beneficial ownership separately.

Key Dates

Keywords

AngioDynamics Inc, Vanguard Group, Schedule 13G, Beneficial Ownership, SEC Filing, Corporate Realignment, Investment Management